Success Stories: A Safer Future in Surgery: EB-2 NIW Approved for Clinical Researcher Focused on Anesthesia and Risk Reduction
Client’s Testimonial:
“Thank you so much for your outstanding support throughout my EB2 process. It was amazing working with Chen attorneys.”
On June 21st, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Resident in the field of Clinical Medicine (Approval Notice).
General Field: Clinical Medicine
Position at the Time of Case Filing: Resident
Country of Origin: Pakistan
State of Residence at the Time of Filing: New York
Approval Notice Date: June 21st, 2025
Processing Time: 1 month, 24 days (Premium Processing Requested)
Case Summary:
In the high-stakes world of clinical medicine, preventing complications before they happen can mean the difference between life and death. One resident physician from Pakistan, now working in the United States, has made that mission his focus. With EB-2 National Interest Waiver (NIW) approval recently secured, his research into perioperative risk factors and anesthetic safety is poised to elevate standards of care across the country.
As a clinical medicine researcher with a background in anesthesiology and critical care, he has conducted influential investigations that redefine how physicians understand and mitigate surgical risks. His work centers on analyzing large-scale patient data to identify high-risk patterns and uncommon complications, particularly within the perioperative period—a time when patients are most vulnerable to adverse outcomes.
Among his notable research efforts is a nationwide study on the risk factors of Posterior Reversible Encephalopathy Syndrome (PRES) in patients with eclampsia. This work revealed how cesarean sections and labetalol therapy correlated with higher incidence rates of PRES, leading to improved treatment protocols that enhance maternal and fetal outcomes. Other projects explored the optimal dosage of erythromycin for ileus management and advanced diagnostic frameworks for acute adult supraglottitis, each contributing practical, lifesaving insight to medical literature.
His growing reputation is supported by a strong publication and citation record: 11 peer-reviewed journal articles, 4 conference abstracts, and 5 book chapters, with a total of 69 citations from scholars in the U.S. and abroad. One of his articles, published in Qatar Medical Journal, is ranked among the top 10% most-cited Clinical Medicine papers for its year of publication, a clear marker of impact.
He has also reviewed at least 9 papers for respected medical journals, such as Anesthesia, Pain and Intensive Care Journal, and Cureus, and currently sits on the editorial board of the Middle Eastern Journal of Medicine and Medical Sciences, a role reserved for recognized authorities in the field.
One of his recommenders, a Chief of Anesthesiology at a U.S. hospital, summed up the significance of his work:
“[Client’s] research contributes to improving perioperative care by refining risk assessment protocols, ultimately helping anesthesiologists and obstetricians prevent severe complications and enhance maternal and neonatal survival rates.”
His NIW petition emphasized how his work aligns with critical national healthcare priorities—namely, improving surgical safety and reducing preventable adverse events. With over 300 million surgeries performed annually worldwide and rising postoperative mortality rates, his evidence-based findings are essential for shaping future protocols in anesthesiology and beyond.At NAILG, we were proud to advocate for his petition and highlight the national importance of his research. With this approval, he can continue conducting high-impact studies and publishing results that will guide clinical decision-making, shape policy, and ultimately save lives.